Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.76 +0.56 (+2.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗
AbbVie still looks like a compelling buy at its all-time high. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Global Oral Contraceptive Drugs Market Growing at 7.3% CAGR Through 2034 ↗
According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to 
Via Talk Markets
News headline image
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out' ↗
Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract. 
Via Benzinga
Topics Government
News headline image
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Absurdly Cheap Dividend Stocks to Buy Before August ↗
Far from "yield traps," these high-yield dividend stocks represent good value at current prices. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. ↗
Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong? 
Via The Motley Fool
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Could it become as successful in this niche as it was in the coronavirus vaccine market? 
Via The Motley Fool
News headline image
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer ↗
Income seekers shouldn't give up on the stock yet. 
Via The Motley Fool
News headline image
3 Healthcare Stocks with Competitive Advantages
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. ↗
A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring. 
Via The Motley Fool
Topics Economy
News headline image
Pfizer Suspends Popular Menopause Cream in India ↗
A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer halts cream distribution. 
Via Benzinga
News headline image
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
It is definitely a strong contender. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
1 Stock Under $50 to Target This Week and 2 We Question
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline... 
Via StockStory
News headline image
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now ↗
Pfizer is a highly respected drug company facing normal industry headwinds. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? ↗
Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut. 
Via The Motley Fool
Topics Intellectual Property
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
All three can be bought on the dip. 
Via The Motley Fool
Topics Intellectual Property
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
3 of the Best Stocks to Buy for Less Than $100 Right Now ↗
These stocks offer a good mix of dividends, growth, and long-term stability. 
Via The Motley Fool
News headline image
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? ↗
The pharma giant's yield of around 7.1% is more than six times the S&P 500 average. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Cathie Wood's biotech ETF has largely moved on from the vaccine maker. 
Via The Motley Fool
Topics ETFs
News headline image
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗
Drug pricing matters, but pipelines matter even more. 
Via The Motley Fool
Topics Government Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Via Chartmill
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
News headline image
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now ↗
These high-yield stocks have long track records of dividend consistency and growth. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.